Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

NCT06151210 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 467

Last updated 2025-08-28

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis

Conditions

  • Gastritis Acute
  • Gastritis Chronic

Interventions

DRUG

DA-5219

1 tablet/day

DRUG

Stillen® Tab

3 tablets/day

DRUG

DA-5219 Placebo

1 tablet/day

DRUG

Stillen® Tab Placebo

3 tablets/day

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-07-10
Completion
2025-07-15

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151210 on ClinicalTrials.gov